The FDA-approved label for Furadantin includes a warning that cases of hemolytic anemia of the primaquine-sensitivity type have been induced by nitrofurantoin, presumably due to G6PD-deficiencies as have been linked to primaquine. Hemolysis is an indication for discontinuing Furadantin.
|Genotype/Genoset||Diplotype||Gene||Drug Use/Category/Class||Medical Field||Summary||Descriptive Sentence|
|gs309||WT/WT||G6PD||Anti-bacterial||Infectious Disease||Normal Response Expected||You do not appear to carry any G6PD mutations linked to an unwanted side effect (hemolytic anemia).|
|gs307||Carrier||G6PD||Anti-bacterial||Infectious Disease||Use with Caution||You carry a G6PD mutation that might lead to an unwanted side effect (hemolytic anemia) when taking nitrofurantoin; be aware of FDA precaution.|
|gs308||G6PD-deficient||G6PD||Anti-bacterial||Infectious Disease||Use with Caution||You carry a G6PD mutation linked to an unwanted side effect (hemolytic anemia) when taking nitrofurantoin; use with caution and monitor for hemolysis.|